BIOGEN INC. Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High
BIOGEN INC. (BIIB) had Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High of $400.00 million as of 2020-12-31, per its 10-K filed 2021-02-03.
Discontinued › Notes › Business Combinations
us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh · last filed 2021-02-03
- 2020-12-31: Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High $400.00M.
- 2019-12-31: Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High $735.00M.
- 2018-12-31: Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High $1.00B.
- 2017-12-31: Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High $1.10B.
| Period end | Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High |
|---|---|
| 2020-12-31 | $400.00M 10-K · filed 2021-02-03 |
| 2019-12-31 | $735.00M 10-K · filed 2020-02-06 |
| 2018-12-31 | $1.00B 10-K · filed 2019-02-06 |
| 2017-12-31 | $1.10B 10-K · filed 2018-02-01 |
| 2016-12-31 | $1.20B 10-K · filed 2017-02-02 |
| 2015-12-31 | $1.30B 10-K · filed 2016-02-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |